Table 1

Clinical and demographic characteristics of the sarcoidosis patients categorized by absence or presence of positive PET findings
PET - patients PET + patients p-value
(n = 18) (n = 77)
age (yrs) 46 (22-72) 45(24-76) 0.585
sex (male) 11 (61%) 44 (57%) 0.762
time since diagnosis (yrs) 4 (1-20) 2 (1-21) 0.469
Therapy total, number (%) 6 (33%) 20 (26%) 0.461
1/2/3/4 3/0/3/0 10/1/7/2 0.444
ACE (9-25 U/L) 15 (1-29) 18 (3-60) 0.136
sIL-2R (240-3154 pg/mL) 1784 (518-4614) 3434 (1191-15000) 0.002
Neopterin (<2.5 ng/mL) 1.7 (0.8-2.6) 2.8 (0.7-18.2) 0.030
CRP (2-9 μg/mL) 6 (1-15) 6 (1-80) 0.249
CXR stage 0/I 12/1 18/14 0.005
CXR stage II/III/IV 1/3/1 12/8/25 0.449
Total HRCT score 2.9 ± 3.0 6.0 ± 3.9 0.002
FVC total (% pred) 90 ± 22 91 ± 22 0.818
CXR I-II 94 ± 24 103 ± 15 0.174
CXR II-IV 79 ± 14 83 ± 22 0.741
DLCO total (% pred) 78 ± 18 69 ± 20 0.046
CXR I-II 79 ± 17 80 ± 17 0.888
CXR II-IV 71 ± 19 60 ± 19 0.234

Data are presented as median with range in parentheses; mean ± SD; absolute numbers or percentages if appropriate. PET: positron emission tomography; -: negative; +: positive; n:number; yrs: years; therapy total: total number of patients treated at time of PET scanning; 1: prednisone monotherapy; 2: methotrexate monotherapy; 3: prednisone and methotrexate combination therapy; 4: methotrexate and infliximab combination therapy; ACE: serum angiotensin-converting enzyme; sIL-2R: soluble interleukin-2 Receptor; CRP: C-reactive protein; CXR: chest radiography; HRCT: high-resolution computed tomography; FVC: forced vital capacity; % pred: percentage of predicted values; DLCO: diffusion capacity for carbon monoxide. p < 0.05 was considered to indicate significance.

Mostard et al.

Mostard et al. BMC Pulmonary Medicine 2012 12:57   doi:10.1186/1471-2466-12-57

Open Data